Novavax (NVAX 9.11%) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported lower-than-expected earnings. The vaccine maker has struggled to win over the investment community after entering the coronavirus vaccine market late with its initial vaccine -- and commercializing its updated vaccine after rivals this past fall. The initial late entry meant Novavax missed out on the biggest revenue opp ...